Quantitative assessment of chemotherapy‐induced peripheral neurotoxicity using a point‐of‐care nerve conduction device

Matsuoka, Ayumu; Mitsuma, Ayako; Maeda, Osamu; Kajiyama, Hiroaki; Kiyoi, Hitoshi; Kodera, Yasuhiro; Nagino, Masato; Goto, Hidemi; Ando, Yumiko

doi:10.1111/cas.13010

Cited by 32 publications

(35 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While there are a limited number of studies which have evaluated this device [ 16 – 18 , 36 , 37 ], one study [ 18 ] showed that this device was a reliable and valid tool for polyneuropathy identification and reported thresholds of ≤6μV for AMP POCD and ≤48m/s for CV POCD in 44 adults with T1D and type 2 diabetes. Comparably, we found that the diagnostic performance and POCD-specific thresholds in older adults with longstanding T1D –despite any age-related changes in nerve conduction–were similar to those reported in younger adults with diabetes, implying that this device can be used as a valid screening test for polyneuropathy across broadly-aged adult populations.…”

Section: Discussionmentioning

confidence: 99%

Validity of a point-of-care nerve conduction device for polyneuropathy identification in older adults with diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes

Scarr¹,

Lovblom²,

Cardinez³

et al. 2018

PLoS ONE

View full text Add to dashboard Cite

ObjectivePoint-of-care nerve conduction devices (POCD) have been studied in younger patients and may facilitate screening for polyneuropathy in non-specialized clinical settings. However, performance may be impaired with advanced age owing to age-related changes in nerve conduction. We aimed to evaluate the validity of a POCD as a proxy for standard nerve conduction studies (NCS) in older adults with type 1 diabetes (T1D).MethodsSural nerve amplitude potential (AMP) and sural nerve conduction velocity (CV) was measured in 68 participants with ≥ 50 years T1D duration and 71 controls (from age/sex-matched subgroups) using POCD and NCS protocols. Agreement was determined by the Bland-Altman method, and validity was determined by receiver operating characteristic curves.ResultsT1D were 53% female, aged 66±8yr and had diabetes duration 54yr[52,58]. Controls were 56%(p = 0.69) female and aged 65±8yr(p = 0.36). Mean AMPPOCD and CVPOCD for the 139 participants was 7.4±5.8μV and 45.7±11.2m/s and mean AMPNCS and CVNCS was 7.2±6.1μV and 43.3±8.3m/s. Mean difference of AMPPOCD−AMPNCS was 0.3±3.8μV and was 2.3±8.5m/s for CVPOCD−CVNCS. A AMPPOCD of ≤6μV had 80% sensitivity and 80% specificity for identifying abnormal AMPNCS, while a CVPOCD of ≤44m/s had 81% sensitivity and 82% specificity to identify abnormal CVNCS. Abnormality in AMPPOCD or CVPOCD was associated with 87% sensitivity, while abnormality in both measures was associated with 97% specificity for polyneuropathy identification.ConclusionsThe POCD has strong agreement and diagnostic accuracy for identification of polyneuropathy in a high-risk subgroup and thus may represent a sufficiently accurate and rapid test for routinely detecting those with electrophysiological dysfunction.

show abstract

Section: Discussionmentioning

confidence: 99%

Validity of a point-of-care nerve conduction device for polyneuropathy identification in older adults with diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes

Scarr¹,

Lovblom²,

Cardinez³

et al. 2018

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Previous studies have mainly investigated the utility of POCD in relation to symptoms and signs of neuropathy, monofilament testing, and 128‐H z tuning fork tests in subjects with diabetes and in patients with chemotherapy‐induced neuropathy . There have been 2 earlier studies comparing the POCD with conventional NCS in 72 and 44 subjects with diabetes.…”

Section: Discussionmentioning

confidence: 99%

The utility of a point‐of‐care sural nerve conduction device for detection of diabetic polyneuropathy: A cross‐sectional study

Kural

Andersen

et al. 2018

Muscle and Nerve

View full text Add to dashboard Cite

Introduction: Rapid and accessible methods for diagnosing diabetic polyneuropathy (DPN) have been developed, but not validated, in large cohorts of people with diabetes. Methods: The performance of a point-of-care device (POCD) was studied in 168 patients with type 2 diabetes, estimating the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) compared with conventional sural nerve conduction studies (NCS). Results: A POCD amplitude limit of 6 μV increased the sensitivity (96%) and NPV (98%), but decreased the specificity (71%) and PPV (54%) compared with the 4-μV limit, which had values of 78%, 92%, 89%, and 71%, respectively. POCD on both legs showed better performance than on 1 leg. POCD amplitudes and conduction velocities correlated significantly with conventional sural NCS, but POCD values were underestimated compared with NCS. Discussion: The POCD may be used as a suitable screening tool for detection of DPN. Patients with abnormal and borderline results should undergo conventional NCS.

show abstract

“…Sensory nerve conduction velocity (SNCV) is used to determine sensory nerves status in all the parameters measured in nerve conduction studies. SNCV accurately reflects the myelin integrity and axon caliber [120]. SNCV is slowed by the demyelination of the sensory nerve fibers.…”

Section: Effects Of Flavonoids On Diabetic Painful Neuropathymentioning

confidence: 98%

In Vitro and In Vivo Effects of Flavonoids on Peripheral Neuropathic Pain

Basu

2020

Molecules

View full text Add to dashboard Cite

Neuropathic pain is a common symptom and is associated with an impaired quality of life. It is caused by the lesion or disease of the somatosensory system. Neuropathic pain syndromes can be subdivided into two categories: central and peripheral neuropathic pain. The present review highlights the peripheral neuropathic models, including spared nerve injury, spinal nerve ligation, partial sciatic nerve injury, diabetes-induced neuropathy, chemotherapy-induced neuropathy, chronic constriction injury, and related conditions. The drugs which are currently used to attenuate peripheral neuropathy, such as antidepressants, anticonvulsants, baclofen, and clonidine, are associated with adverse side effects. These negative side effects necessitate the investigation of alternative therapeutics for treating neuropathic pain conditions. Flavonoids have been reported to alleviate neuropathic pain in murine models. The present review elucidates that several flavonoids attenuate different peripheral neuropathic pain conditions at behavioral, electrophysiological, biochemical and molecular biological levels in different murine models. Therefore, the flavonoids hold future promise and can be effectively used in treating or mitigating peripheral neuropathic conditions. Thus, future studies should focus on the structure-activity relationships among different categories of flavonoids and develop therapeutic products that enhance their antineuropathic effects.

show abstract

Quantitative assessment of chemotherapy‐induced peripheral neurotoxicity using a point‐of‐care nerve conduction device

Cited by 32 publications

References 23 publications

Validity of a point-of-care nerve conduction device for polyneuropathy identification in older adults with diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes

Validity of a point-of-care nerve conduction device for polyneuropathy identification in older adults with diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes

The utility of a point‐of‐care sural nerve conduction device for detection of diabetic polyneuropathy: A cross‐sectional study

In Vitro and In Vivo Effects of Flavonoids on Peripheral Neuropathic Pain

Contact Info

Product

Resources

About